Patent Ductus Arteriosus

0
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
2 programs
AMPLATZER Duct Occluder IIN/A2 trials
Amplatzer Piccolo OccluderN/A1 trial
Active Trials
NCT03055858Completed200Est. Apr 2022
NCT00713700Completed192Est. Oct 2016
NCT04371081Active Not Recruiting70Est. Jul 2027
Cook Medical
Cook MedicalIN - Bloomington
1 program
IbuprofenN/ASmall Molecule1 trial
Active Trials
NCT01758913CompletedEst. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AbbottAmplatzer Piccolo Occluder
AbbottAMPLATZER Duct Occluder II
AbbottAMPLATZER Duct Occluder II
Cook MedicalIbuprofen

Clinical Trials (4)

Total enrollment: 462 patients across 4 trials

NCT04371081AbbottAmplatzer Piccolo Occluder

Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance

Start: Apr 2020Est. completion: Jul 202770 patients
N/AActive Not Recruiting
NCT03055858AbbottAMPLATZER Duct Occluder II

AMPLATZER Duct Occluder II Additional Sizes

Start: Jun 2017Est. completion: Apr 2022200 patients
N/ACompleted
NCT00713700AbbottAMPLATZER Duct Occluder II

AMPLATZER Duct Occluder II Clinical Study

Start: Aug 2008Est. completion: Oct 2016192 patients
N/ACompleted
NCT01758913Cook MedicalIbuprofen

Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants

Start: Feb 2007Est. completion: Feb 2012
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space